Evidence map›Paper›PMID 33953789›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2021

A Network Pharmacology Approach to Predict the Proangiogenesis Mechanism of Huangqi-Honghua Herb Pair after Cerebral Ischemia.

Jinyi Cao, Lu Lei, Kai Wang, Jing Sun, Yi Qiao, Jialin Duan, Chao Zhao, Jia Cui, Zhijun Feng, Jing-Wen Wang and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Jinyi CaoDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.ORCID https://orcid.org/0000-0002-3404-5878
Lu LeiSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Kai WangCollege of Pharmacy, Shaanxi University of Chinese Medicine, Xianyan 712046, China.
Jing SunDepartment of Anesthesiology, Northwest Women's and Children's Hospital, Xi'an 710061, China.
Yi QiaoDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Jialin DuanDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Chao ZhaoDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Jia CuiDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.ORCID https://orcid.org/0000-0001-8788-6833
Zhijun FengDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Jing-Wen WangDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.ORCID https://orcid.org/0000-0002-3450-9046
Aidong WenDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Zhifu YangDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.ORCID https://orcid.org/0000-0002-2093-2644
Xijing Hospital · CNChina Pharmaceutical University · CNNorthwest Women's and Children's Hospital · CNShaanxi University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHuangqi-Honghua herb pair is known for its medicinal value to treat Qi deficiency and blood stasis syndrome with a long history in clinical practice. To understand its possible mechanism in a systematic study, a network pharmacological method was addressed.

methodsDetailed information on the HH compounds was obtained from two public databases, and oral bioavailability (OB) and drug-like (DL) of the compounds were evaluated. A correlation between HH compounds, its potential targets, and known targets was extrapolated, and the herb-compound-target-disease (H-C-T-D) network was established. Next, the pathway enrichment and essential genes were analyzed. Then, three key genes (VEGFA, VEGFR2, and eNOS), highly associated with angiogenesis, were screened and verified through western blot assay.

resultsOut of 276 compounds, 21 HH compounds and 78 target genes regulating the major pathways associated with CI in the network are analyzed. The bioactive compounds in HH were active in various signal transduction pathways such as the toll-like receptor signaling pathway, VEGF signaling pathway, TNF signaling pathway, and HIF-1 signaling pathway are important pathways that may regulate anti-inflammatory, antiapoptotic, immune correlation, and antioxidative effects. The core genes are PTGS2, TNF, NOS2, IL6, BCL2, IL1B, SOD2, NOS3, SOD1, MMP9, and VEGFA. The in vitro results suggested that HH treatment could significantly elevate the expression of proangiogenic genes such as VEGFA, VEGFR2, and eNOS compared with OGD groups.

conclusionsOur results predict that HH may regulate the expression of VEGFA, VEGFR2, and eNOS via the VEGF and HIF-1 signaling pathway to promote angiogenesis and alleviate cerebral ischemia injury.

Identifiers

PMID33953789
PMCPMC8064780
OpenAlexW3153277869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.